Skip to main content
OpenTrials

Clinical trial condition

Overactive Bladder

Explore clinical trials studying Overactive Bladder. Study availability and eligibility vary by location and protocol.

362 public trials 25 recruiting studies
Refine in advanced search Browse all conditions

Overactive Bladder trial results

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768

Conditions
Benign Prostatic Hyperplasia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
Locations
  • Site US01009 Homewood, Alabama, United States
  • Site US01005 Huntsville, Alabama, United States
  • Site US01012 Anchorage, Alaska, United States
  • Site US01070 Hawaiian Gardens, California, United States
View all 79 locations
View Trial Details
Completed

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

NCT02656173

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, +13 more
Locations
  • Site JP81046 Aichi, Japan
  • Site JP81009 Chiba, Japan
  • Site JP81045 Chiba, Japan
  • Site JP81041 Fukuoka, Japan
View all 58 locations
View Trial Details
Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +15 more
Locations
  • Site US10049 Coastal Clinical Research, Inc. Mobile, Alabama, United States
  • Site US10112 TFI, LLC Mobile, Alabama, United States
  • Site US10104 Clinical Research Advantage, Inc. Chandler, Arizona, United States
  • Site US10021 Beach Clinical Studies Phoenix, Arizona, United States
View all 435 locations
View Trial Details
Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +15 more
Locations
  • Site US10049 Mobile, Alabama, United States
  • Site US10112 Mobile, Alabama, United States
  • Site US10104 Chandler, Arizona, United States
  • Site US10021 Phoenix, Arizona, United States
View all 251 locations
View Trial Details
Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

NCT02320773

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +11 more
Locations
  • Site CZ42009 UROMEDA s. r. o. Brno, Czechia
  • Site CZ42003 Fakultni nemocnice Brno-Bohunice Brno, Czechia
  • Site CZ42006 Hospital Kyjov Kyjov, Czechia
  • Site CZ42002 Fakultni nemocnice Kralovske Vinohrady Prague, Czechia
View all 60 locations
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

NCT02526979

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +10 more
Locations
  • Site DK45002 Aalborg, Denmark
  • Site DK45001 Aarhus, Denmark
  • Site PL48001 Warsaw, Poland
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

NCT02211846

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, +11 more
Locations
  • Site BE32009 Univ.Ziekenhuis Antwerpen Edegem, Belgium
  • Site BE32003 Gent University Hospital Ghent, Belgium
  • Site BE32004 AZ Groeninge, Campus Vercruyss Kortrijk, Belgium
  • Site BE32011 U.Z. Leuven Leuven, Belgium
View all 13 locations
View Trial Details

Related conditions